Fig. 3
From: Anti-BCL2 therapy eliminates giant congenital melanocytic nevus by senolytic and immune induction
BCL2 inhibitor induces significant regression and leukotrichia in GCMN lesions of H11-Tyr-NrasQ61K mice. a, b Assessment of treatment efficacy based on phenotypic and dermoscopic evaluations 14 days post-injection of DMSO, Trametinib, or Venetoclax in the GCMN lesions of H11-Tyr-NrasQ61K mice. c, d Phenotypic observations and dermoscopic images of hair regrowth 90 days after intralesional injections with DMSO, Trametinib, or Venetoclax in shaved H11-Tyr-NrasQ61K mice. e Spontaneously regressed human GCMNs exhibiting hypopigmentation and leukotrichia, resembling the regressed mouse GCMN phenotypes. f Analysis of melanin content using a Mexameter MX18 detector from the CKMPA10 instrument, performed 14 days after Venetoclax intralesional injection (n = 6 mouse for each group). Mean ± SD. g Hematoxylin and eosin (HE) staining and immunostaining demonstrating the histological changes and the MelanA+ GCMN cells in the skin after 14 days of intralesional injection with DMSO, Trametinib, or Venetoclax. Scale bar=100μm and 50μm. h Bar graph indicating the number of remaining MelanA+ GCMN cells in the skin 14 days after intralesional injection of DMSO, Trametinib, or Venetoclax (n = 6 mouse for each group). Mean ± SD
